Buy P21 Nootropic Peptide – P21 Nasal Spray
P21 is a new nootropic peptide that currently hasn’t undergone clinical trials but has lots of research and user reports, after being sold by Ceretropic.
Nootropics frequently target similar pathways to improve neurogenesis.
What Is P21?
P-21 is a heavily modified peptide nootropic that was originally designed from CNTF antibodies, not Cerebrolysin, as is commonly thought. Cerebrolysin was the motivation to research CNTF antibodies, as it was shown to be responsible for its neurogenesis elements [R].
The ambition with the P21 nootropic drug was to “incorporate new neurons into already existing neural networks”, to battle the crippling disease called Alzheimer’s. Despite the ongoing and continual research behind P-21, there exist no clinical trials.
How Does the P-21 Nootropic Work?
It works by inhibiting something that inhibits neurogenesis in the dentate gyrus.
The factor that inhibits neurogenesis is called Leukaemia inhibiting factor (LIF). P021 does not bind to CNTFr.
There are a wide range of effects induced by P-21, such as increased BDNF levels, higher AMPA receptor protein levels, (Glur2 and or Glur3), and higher Phosphorylated GSK3B levels.
Higher Ki67 levels indicate higher levels of mitosis processes [R]. Mitosis is the splitting of one cell into two cells, a vital stage of neurogenesis. There was an approximate 150% increase in mitotic cells in the dentate gyrus compared to wild-type (non Alzheimer’s) after 9-month treatment with P021.
It’s not with every compound that you find a compound that can improve Alzheimer’s beyond healthy controls!
Higher DCX levels indicate the maturation of neural precursor cells [R]. However, there is a sex-dependent difference in DCX, and almost every P021 study uses exclusively females.
Most use females because Tau Diseases are more aggressive in female mice [R].
There was a 100% increase in DCX cells in the dentate gyrus after 9 month treatment with P021 compared to wild type mice.
